Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. (Q37909894)

25 August 2017

1 reference

title

Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292196&resulttype=core&format=json

13 May 2020

1 reference

Steven A Rosenberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292196&resulttype=core&format=json

13 May 2020

language of work or name

English

0 references

publication date

2 August 2011

1 reference

Nature Reviews Clinical Oncology

25 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292196&resulttype=core&format=json

13 May 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292196&resulttype=core&format=json

13 May 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292196&resulttype=core&format=json

13 May 2020

page(s)

577-585

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292196&resulttype=core&format=json

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Structure and expression of a cloned cDNA for human interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

A new era for cancer immunotherapy based on the genes that encode cancer antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Adoptive cell therapy for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Adoptive immunotherapy for cancer: building on success

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Adoptive cell therapy: genetic modification to redirect effector cell specificity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Cancer/testis antigens, gametogenesis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.116

Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21808266

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21808266

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21808266

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2011.116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292196&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6292196&resulttype=core&format=json

13 May 2020

1 reference